Accumulated evidence indicates that ACE2, a gatekeeper of RAS that coronaviruses use as a host functional receptor, is a potential therapeutic target due to its degrading effects on AngII in hypertension, LV hypertrophy, fibrosis, and diastolic dysfunction, including cardiovascular complication in COVID-19 (9, 39). This evidence concerns the gene AGT and hypertensive disorder.